FDA Calendar

2016 Biotech Calendar and beyond for your biotech investing. Biotech Catalyst Calendar. Biotech stocks, FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial data releases dates.

Data are current and updated daily!

IMPORTANT: The BioPharmCatalyst FDA Calendar is NOT an official calendar. It has absolutely NO affiliation with the FDA. The calendar is created using company SEC filings and press releases.

IMPORTANT: Note that the catalyst date is the LATEST expected date for the catalyst to occur by.

For example, if the catalyst date is 12/31/16, this means it is expected to occur BY 12/31/16. It does not necessarily mean that the catalyst will occur ON this date. In most cases it will occur well BEFORE the date.

Please READ the CATALYST NOTES in the RIGHT HAND COLUMN for FULL details and click the link in the right column to access the relevant press release.

Please refer to the “FDA Calendar Glossary” for a list of terms used in the FDA Decision Calendar.

AMEX and NASDAQ companies are listed. Generally no OTC/PINK companies are listed unless the upcoming catalyst is a PDUFA or Advisory Committee event.

LARGE cap companies are generally NOT featured in the database.

TickerPriceMktCapTypeCatalyst Date (due by)Catalyst Notes - click for details
HRTX16.19625.1mPDUFANoted on March 3 the FDA will make a decision on its NDA Sustol for prevention of acute and delayed-onset chemotherapy-induced nausea and vomiting (CINV), by early April 2016. Further update provided April 18, 2016 that indicated that the FDA noted there are no substantive deficiencies in the NDA and they have begun labeling discussions
SRPT22.651.2bPDUFACompany noted on May 25, 2016 a PDUFA goal date delay for the NDA of eteplirsen. No timeline given.
HRTX16.19625.1mPhase 2Phase 2 data of HTX-011 for hernia repair and bunionectomy due mid July 2016
OCUL5.15137.8mPDUFA07/24/2016PDUFA July 24 2016 of DEXTENZA for Ocular inflammation and pain following cataract surgery
ADMA6.3881.6mPDUFABLA filing was announced on July 31 2015 for RI-002 for primary Immune Deficiency Diseases. The FDA states that they act on original BLA submissions within 12 months, which would generate a PDUFA date on or around July 30 2016. However, the company have not given a specific date, rather stated that a decision is due 2H 2016. Company IR have been contacted to clarify the PDUFA date. No response to date.
BMRN93.3615.7bNDA filing07/31/2016NDA filing of Cerliponase alfa for Batten Disease due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
CCXI4.68212.8mPhase 1b07/31/2016Phase 1b early response data of CCX872 for Non-resectable pancreatic cancer due mid 2016. Initial PFS data due 2H 2016
CORT5.86655.9mPhase 1/207/31/2016Phase 1/2 data of mifepristone in combination with eribulin for triple-negative breast cancer due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
CYCC4.9014.0mPhase 307/31/2016Phase 3 top-line data of Sapacitabine (SEAMLESS) trial for Acute myeloid leukemia due around mid 2016. Company noted mid-Dec 2014 that interim analysis suggests that trial will fail. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
GWPH93.752.4bPhase 2b07/31/2016Phase 2 data of GWP42004 for Type 2 diabetes late 2Q or early 3Q 2016
KMDA3.92143.5mBLA filing07/31/2016BLA filing of KamRAB for Prophylaxis of rabies disease due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
KMDA3.92143.5mPhase 207/31/2016Phase 2 top-line data of Inhaled formulation of AAT for AATD - Alpha-1 Antitrypsin deficiency due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
KPTI7.14257.1mPhase 207/31/2016Phase 2 top-line data of Selinexor - STORM trial for Quadruple Refractory Multiple Myeloma due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
MCRB33.661.4bPhase 207/31/2016Phase 2 data of SER-109 for Recurrent C. Difficile infection due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
MRNS2.0242.3mPhase 207/31/2016Phase 2 data of Ganaxolone in patients with PCDH19 due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
MSTX0.4178.8mPhase 307/31/2016Phase 3 database lock of ANX-188 for Sickle cell disease (EPIC trial) due in July with top-line data due shortly thereafter. July 31 BPC estimate only. August is a possibility for data release
SCYX2.2554.5mPhase 207/31/2016Phase 2 topline data of SCY-078 for Invasive Candida infections due July 2016
THLD0.5036.2mPhase 207/31/2016Phase 2 prelim data of Tarloxotinib for Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
THLD0.5036.2mPhase 207/31/2016Phase 2 preliminary data of Tarloxotinib for mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
TLOG0.328.1mPhase 207/31/2016Phase 2 final data of SHAPE trial for Cutaneous T-Cell Lymphoma due mid 2016. NOTE! July 31 is a BPC ESTIMATE ONLY as the LAST likely date for database purposes only based on company guidance of mid 2016.
EGLT6.40172.7mAdvisory Committee08/04/2016Advisory Committee Meeting scheduled for August 4 2016 for ARYMO ER (Egalet-001) - Abuse-Deterrent Morphine
PTLA23.931.4bPDUFA Priority Review08/17/2016PDUFA date August 17 2016 under priority review for the BLA filing of Andexanet alfa, a Factor Xa inhibitor reversal agent
ARRY3.63538.4mPhase 208/30/2016Phase 2 data of ARRY 797 for LMNA A/C-related dilated cardiomyopathy (DCM) to be presented at the European Society of Cardiology on August 30, 2016
CHRS23.981.1bBLA filing08/31/2016CHS-1701 (Pegfilgrastim biosimilar) PK/PD study to be completed by the end of 1H 2016 with BLA to filed directly after. August 30 2016 BPC estimate only
EARS3.77130.6mPhase 308/31/2016Phase 3 topline data of AM-101 for Acute inner ear tinnitus due August 2016
IPCI1.5939.9mNDA filing08/31/2016NDA filing of Rexista for Pain relief due August 2016
RIGL2.23207.3mPhase 308/31/2016Phase 3 data from the first of two trials of Fostamatinib for Immune Thrombocytopenic Purpura (ITP) due August 2016 with the second in October - Source: June webcast
SYN1.66157.9mPhase 2b08/31/2016Phase 2b interim analysis SYN-004 in patients with C. difficile Infection due summer of 2016. August 31 2016 date used as an estimate only for database purposes
VTVT5.55186.7mPhase 208/31/2016Phase 2 results of TTP399 - AGATA for the treatment of Type 2 Diabetes due summer 2016
ARLZ3.56223.2mPDUFA09/14/2016PDUFA date September 14 2016 for YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers
DRRX1.65243.3mPDUFA09/25/2016PDUFA September 25 2016 for Remoxy for Chronic pain
PTIE2.55125.6mPDUFA09/25/2016PDUFA September 25 2016 for Remoxy for Chronic pain
ABUS4.21236.2mPhase 209/30/2016Phase 2 HBsAg reduction results from single dose of ARB-1467 (TKM-HBV, RNAi) for Hepatitis B virus infection (HBV) due 3Q 2016, multiple dose data due 4Q 2016
ACHN8.771.2bPhase 2a09/30/2016Phase 2a topline data of Odalasvir, simeprevir and ALS-335 for Hepatitis C viral infection (HCV) due 3Q 2016
ACRS20.98461.3mPhase 309/30/2016Phase 3 data of of A-101 for Seborrheic keratosis (SK) due 3Q 2016
ACRS20.98461.3mPhase 209/30/2016Phase 2 data of A-101 for Common warts (verruca vulgaris) due 3Q 2016
ACRX2.94134.6mPhase 309/30/2016Phase 3 top-line data of ARX-04 for Moderate-to-severe acute pain due 3Q 2016
AERI17.91489.8mNDA filing09/30/2016NDA filing of Rhopressa for Glaucoma due 3Q 2016
AERI17.91489.8mPhase 309/30/2016Phase 3 Mercury 1 data of Roclatan for Glaucoma due 3Q 2016. Mercury 2 trial data due 2Q 2017
AEZS3.5135.8mPhase 309/30/2016Phase 3 completion of Macrilen for Adult Growth Deficiency expected to be completed 3Q 2016
AEZS3.5135.8mPhase 309/30/2016Phase 3 trial of Zoptrex for castration and taxane resistant prostate cancer to be completed 3Q 2016
ALDR27.211.4bPhase 2b09/30/2016Phase 2b 24 week data of ALD403 for Chronic Migraine due 3Q 2016
ALDX5.7057.1mPhase 209/30/2016Phase 2 data of NS2 for Sjögren-Larsson Syndrome (SLS) due 3Q 2016
APRI0.3420.5mNDA filing09/30/2016NDA filing of Vitaros for Erectile dysfunction to be resubmitted 3Q 2016
ARRY3.63538.4mPhase 309/30/2016Phase 3 data of MEK162 (ARRY-162) - COLUMBUS trial for BRAF mutant melanoma due 3Q 2016
AUPH3.03106.6mPhase 2b09/30/2016Phase 2b data of Voclosporin for Lupus due 3Q 2016
CLCD8.85134.7mPhase 309/30/2016Phase 3 Top-line data of Lasmiditan - SAMURAI trial for Migraine available 3Q 2016.
CYTX2.05399.6mPhase 209/30/2016Phase 2 full data of ECCO-50 cellular therapeutic for Osteoarthritis of the knee due 3Q 2016. Noted in February 2016 that interim data showed the pre-specified primary endpoint did not obtain statistical significance.
DPRX10.47110.1mPhase 309/30/2016Phase 3 top-line data of Locilex for Mild infections of diabetic foot ulcers, due 3Q 2016
ESPR11.31266.4mPhase 209/30/2016Phase 2 (PK/PD) top-line data of ETC-1002 in combination with high-dose statins (HDS) due 3Q 2016
GNCA4.07116.8mPhase 2b09/30/2016Phase 2b virologic efficacy data of GEN-003 for the treatment of genital herpes due 3Q 2016. 6-month efficacy data due late 2016
GWPH93.752.4bPhase 309/30/2016First Phase 3 trial data of Epidiolex for Lennox-Gastaut syndrome (LGS) due June 2016. Data from second trial due 3Q 2016
INFI1.6085.5mPhase 309/30/2016Phase 3 interim analysis of Duvelisib - DUO trial for relapsed/refractory chronic lymphocytic leukemia (CLL) due early 3Q 2016
KERX7.51813.2mNDA filing09/30/2016sNDA of Auryxia for Iron deficiency anemia in non-dialysis dependent CKD patients to be filed 3Q 2016
NVAX7.442.1bPhase 309/30/2016Phase 3 data of RSV F Vaccine - Resolve trial for the prevention of moderate-severe RSV-associated lower respiratory tract disease due 3Q 2016
OGXI0.9228.4mPhase 309/30/2016Phase 3 final data of Custirsen in combination with Jevtana (cabazitaxel) - AFFINITY trial for castrate-resistant prostate second-line cancer due 3Q 2016 but have already noted that a subpopulation who had multiple poor prognostic risk factors did NOT show improvement in survival
PRTK12.83284.6mPhase 309/30/2016Phase 3 data of Omadacycline for Community-acquired bacterial pneumonia (CABP) are due 3Q 2017
PTN0.5435.9mPhase 309/30/2016Phase 3 top-line data of Bremelanotide for female sexual dysfunction (FSD) due 3Q 2016
RPRX1.7138.0mPhase 209/30/2016Phase 2 3-month and 6-month data of Enclomiphene for the treatment of Secondary Hypogonadal Men are due 3Q 2016
SNDX12.14219.3mPhase 1/209/30/2016Phase 1b confirmation stage of Entinostat plus Keytruda - ENCORE 601 trial for Recurrent non-small cell lung cancer (NSCLC) to be completed 3Q 2016
TBRA10.96120.3mPhase 2b09/30/2016Phase 2b data of Cenicriviroc (CVC) - CENTAUR study for Non-alcoholic Steatohepatitis (NASH) due 3Q 2016
TNXP1.9650.4mPhase 309/30/2016Phase 3 data of TNX-102 SL for Fibromyalgia due 3Q 2016
VICL4.3941.3mPhase 209/30/2016Phase 2 data of ASP0113 Vaccine for Kidney transplant recipients due 3Q 2016
VRTX93.2124.0bPhase 309/30/2016Phase 3 interim analysis of VX-661 for Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function, due 3Q 2016
VRTX93.2124.0bPDUFA Priority Review09/30/2016PDUFA date under priority review of September 30 2016 for ORKAMBI in patients with Cystic fibrosis (CF) ages 6-11 who have F508del mutation
VSAR11.22340.5mPhase 209/30/2016Phase 2 data of VRS-317 VITAL trial for Growth hormone deficiency, or GHD in adults due 3Q 2016
WINT1.9016.1mPhase 2a09/30/2016Phase 2a data of Aerosurf for Respiratory Distress Syndrome due 3Q 2016
EGLT6.40172.7mPDUFA10/14/2016PDUFA October 14 2016 for Egalet-001 an abuse-deterrent morphine
MDVN62.5410.3bPDUFA10/22/2016PDUFA October 22 2016 for sNDA of Enzalutamide for prostate cancer
PRQR4.78112.7mPhase 1b10/27/2016Phase 1b preliminary data of QR-010 for Cystic Fibrosis due at the North American Cystic Fibrosis Conference (NACFC) October 27 - 29, 2016
LXRX15.411.7bPDUFA Priority Review10/30/2016PDUFA November 30, 2016 under priority review of Telotristat etiprate for Carcinoid Syndrome
CYNA16.73195.3mPhase 310/31/2016Phase 3 top-line efficacy data of APL-130277 - CTH-300 trial for OFF episodes in patients with Parkinson’s disease due 3Q or early 4Q 2016
TBPH22.261.1bPhase 310/31/2016Phase 3 data of Revefenacin for COPD due late 3Q or early 4Q 2016
THERF1.98132.0mPhase 310/31/2016Phase 3 24 week treatment trial of Ibalizumab for Multi-drug resistant HIV-1 patients to be completed by end of October 2016
AMRN2.33434.1m10/31/2016REDUCE-IT outcomes trial interim efficacy look by the independent Data Monitoring Committee (DMC) expected around September or October 2016.
INNL5.51175.3mPhase 310/31/2016Phase 3 data of Cogenzia for Diabetic foot ulcer infections due 3Q or early 4Q 2016
VRX24.488.7bPDUFA11/16/2016PDUFA date of Brodalumab Subcutaneous Injection for Moderate to Severe Plaque Psoriasis November 16 2016. Advisory Committee Meeting July 16 2016
BLUE48.881.9bPhase 1/212/03/2016Phase 1/2 trial updated data of LentiGlobin for β-Thalassemia expected at ASH December 2016
BLUE48.881.9bPhase 1/212/03/2016Phase 1/2 trial updated data of LentiGlobin for Sickle disease expected at ASH December 2016
SPPI6.50465.0mPDUFA12/11/2016PDUFA December 11 2016 for Apaziquone for the treatment of bladder cancer. Advisory Committee Meeting likely to be scheduled.
DVAX15.31621.6mPDUFA12/15/2016PDFUA December 15 2016 of HEPLISAV-B for Hepatitis B
CEMP17.83886.1mPDUFA12/27/2016PDUFA date December 27 2016 for Solithera - oral for Community-acquired bacterial pneumonia (CABP)
CEMP17.83886.1mPDUFA12/28/2016PDUFA date December 27 2016 for Solithera - intravenous for Community-acquired bacterial pneumonia (CABP)
AAAP30.691.2bPDUFA priority review12/28/2016PDUFA date under priority review December 28, 2016 of Lutathera for Inoperable progressive midgut NETs
ACHN8.771.2bPhase 212/31/2016Phase 2 interim data of ACH-4471 for Paroxysmal nocturnal hemoglobinuria (PNH) due by end of 2016
ACOR25.411.3bPhase 312/31/2016Phase 3 data of Dalfampridine for Post stroke deficits due 4Q 2016
ACOR25.411.3bPhase 312/31/2016Phase 3 data of CVT-301 for OFF episodes of Parkinson’s disease (PD) due 4Q 2016
ADHD4.31121.6mPhase 312/31/2016Phase 3 data of MDX (Metadoxine Extended Release (MG01CI) for Adult ADHD due by the end of 2016
ADMS16.24351.0mNDA filing12/31/2016NDA filing of ADS-5102 for Levodopa-Induced Dyskinesia due 2016
ADRO13.67920.1mPhase 2b 12/31/2016Phase 2b interim data of CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial for Pancreatic cancer to be released 2H 2016
ALKS48.977.6bNDA filing12/31/2016sNDA filing of Aristada (2-month option) for Schizophrenia due 2H 2016
ALKS48.977.6bPhase 312/31/2016Phase 3 FORWARD-5 data, the third of three trials of ALKS 5461 for Major depressive disorder, due by end of 2016
ALNY64.975.7bPhase 1/212/31/2016Phase 1/2 initial data of ALN-GO1 for Primary Hyperoxaluria Type 1 (PH1) due late 2016
ANTH3.08125.7mPhase 312/31/2016Phase 3 top-line data of Sollpura (liprotamase) for Cystic fibrosis who suffer from exocrine pancreatic insufficiency due end of 2016
ANTH3.08125.7mPhase 312/31/2016Phase 3 final data of Blisibimod for Lupus due 2H 2016.
ARIA7.981.7bPhase 212/31/2016Phase 2 dose ranging trial preliminary data of Iclusig (ponatinib) for third line chronic-phase CML (CP-CML) due end of 2016
ARRY3.63538.4mPhase 312/31/2016Phase 3 data of Selumetinib SELECT-1 trial for differentiated thyroid cancer due 2H 2016
AVIR1.3954.5mPhase 2b12/31/2016Phase 2b top-line data of Vapendavir for Human rhinovirus (HRV) due 2H 2016
BLRX0.7743.4mPhase 212/31/2016Phase 2 partial data of BL-8040 for the mobilization and collection of bone marrow stem cells due by end of 2016 with topline data due by the end of 2017
CATB3.5052.4mPhase 212/31/2016Phase 2 data of CAT-1004 for Duchenne muscular dystrophy (DMD) due late 2016
CCXI4.68212.8mPhase 212/31/2016Phase 2 data of CCX168 for atypical Hemolytic Uremic Syndrome (aHUS) due 2016
CERC2.3921.3mPhase 212/31/2016Phase 2 data of CERC-501 for Smoking cessation due 4Q 2016
CERU2.8684.9mPhase 212/31/2016Phase 2 data of CRLX101, in combination with Avastin for Renal Cell Carcinoma due 2H 2016
CERU2.8684.9mPhase 1b/212/31/2016Further interim Phase 1b/2 data of CRLX101 in Combination with Chemotherapy and Radiation for rectal cancer due 2H 2016
CERU2.8684.9mPhase 212/31/2016Phase 2 interim data of CRLX101, in combination with Avastin for ovarian cancer due 2H 2016
CHRS23.981.1bPhase 312/31/2016Phase 3 data of CHS-1420 for Psoriasis due 2H 2016
CLDX4.74486.7mPhase 212/31/2016Phase 2 data of Glembatumumab vedotin for melanoma to be presented 2H 2016
CPXX30.241.3bNDA filing12/31/2016NDA filing of VYXEOS for Secondary AML planned for 2016
CRBP2.83128.7mPhase 212/31/2016Phase 2 data of Resunab for Cystic Fibrosis due 4Q 2016
CRBP2.83128.7mPhase 212/31/2016Phase 2 data of Resunab for Systemic Sclerosis due 4Q 2016
CRMD1.5957.2mPhase 312/31/2016Phase 3 interim analysis of Neutrolin - LOCK-IT 100 trial for Hemodialysis patients with central venous catheters due by end of 2016
CYTR0.6058.1mPhase 2b12/31/2016Phase 2b data of Aldoxorubicin for relapsed/refractory small cell lung cancer due 2H 2016
CYTR0.6058.1mPhase 212/31/2016Phase 2 overall survival data of Aldoxorubicin for unresectable glioblastoma due 2H 2016
DMTX7.29200.3mPhase 1/212/31/2016Phase 1/2 cohort data of DTX101 for hemophilia B due 2H 2016
EARS3.77130.6mPhase 312/31/2016Phase 3 topline data of AM-101 - TACTT3 trial for Acute inner ear tinnitus due 4Q 2016
EXEL8.592.0bPhase 212/31/2016Phase 2 data of Cabozantinib for recurrent endometrial cancer due 2016
FLXN16.58465.2mNDA filing12/31/2016NDA filing of Zilretta for Osteoarthritis of the knee to be filed 4Q 2016
FOLD5.87767.3mPhase 212/31/2016Phase 2 interim data of ATB200 for Pompe Disease due 2016
FOLD5.87767.3mPhase 312/31/2016Phase 3 top-line data of SD-101 for Epidermolysis Bullosa (EB) due 2H 2016
FOMX7.10220.0mPhase 212/31/2016Phase 2 top-line data of FDX103 for Papulopustular rosacea due by the end of 2016
GALE0.47125.6mPhase 2b12/31/2016Phase 2b interim safety data and patient immunology data on the A24 and A25 Human Leukocyte Antigen (HLA) status due 4Q 2016 for NeuVax in combination with Herceptin for breast cancer
GBIM0.936.0mPhase 212/31/2016Phase 2 48-week results of GS-4774 - 0101 trial - for chronic hepatitis B infection are expected to be available 2H 2016
GBIM0.936.0mPhase 212/31/2016Phase 2 data of GI-6207 for MTC (medullary thyroid cancer) due 2H 2016
GERN2.70444.2mPhase 212/31/2016Internal review of Phase 2 Imetelstat - IMerge Study to be conducted 2H 2016
GERN2.70444.2mPhase 212/31/2016Internal review of Phase 2 Imetelstat - Imetelstat - IMbarkStudy to be conducted 2H 2016
GLMD4.1645.1mPhase 2b01/31/2017Phase 2b Interim analysis of Aramchol for Non-Alcoholic Steatohepatitis (NASH) due December 2016 or early 2017. Final Data due 1Q 2018
GTXI0.5879.5mPhase 212/31/2016Phase 2 top-line data of Enobosarm for Postmenopausal women with stress urinary incontinence (SUI) are due 2016
GTXI0.5879.5mPhase 212/31/2016Phase 2 prelim data of Enobosarm advanced AR+ TNBC due by end of 2016
GTXI0.5879.5mPhase 212/31/2016Phase 2 prelim data of Enobosarm for metastatic or locally advanced, ER+/AR+ breast cancer due by end of 2016
GWPH93.752.4bPhase 312/31/2016Top line Phase 3 data of Epidiolex for Dravet Syndrome expected 2H 2016 (second trial)
GWPH93.752.4bPhase 212/31/2016Phase 2 data of Sativex for Multiple Sclerosis (MS) spasticity due 4Q 2016
HALO9.351.3bPhase 212/31/2016Phase 2 PFS data of PEGPH20 for pancreatic cancer due 4Q 2016
HRTX16.19625.1mNDA filing12/31/2016NDA filing of HTX-019 for the prevention of chemotherapy-induced nausea and vomiting (CINV) due 2H 2016
HTBX0.8619.8mPhase 212/31/2016Phase 2 data of HS-410 for bladder cancer due 4Q 2016
HTBX0.8619.8mPhase 1b12/31/2016Phase 1b topline data of HS-110 for NSCLC non-small cell lung cancer due 4Q 2016
HZNP19.073.1bPhase 312/31/2016Phase 3 data of ACTIMMUNE for Friedreich's Ataxia (FA) due by the end of 2016
IMDZ7.38156.9mPhase 212/31/2016Phase 2 first analysis of CMB305 for solid tumors due 4Q 2016
IMGN2.85260.5mPhase 312/31/2016Phase 3 data of Kadcyla - KRISTINE trial - for patiets with HER2-positive breast cancer - neo-adjuvant setting, due 2016
INCY87.7917.3bPhase 212/31/2016Phase 2 data of Ruxolitinib for Breast Cancer due 2016
INCY87.7917.3bPhase 212/31/2016Phase 2 data of Ruxolitinib for Colorectal cancer due 2016
IONS27.753.4bPhase 212/31/2016Phase 2 data of IONIS-FXIRx for End-stage renal disease due 2016
IRWD13.842.1bPhase 2b12/31/2016Phase 2b data of Linaclotide Colonic Release for Irritable Bowel Syndrome with Constipation (IBS-C) due 2H 2016
ITEK8.88244.9mPhase 312/31/2016Phase 3 top-line data of Rabodenoson for Primary open-angle glaucoma (POAG) due 4Q 2016
KITE50.182.6bPhase 2 pivotal12/31/2016Phase 2 pivotal interim data of KTE-C19 (ZUMA-1) for Refractory Non-Hodgkin's Lymphoma (NHL) due 2H 2016 with BLA filing due late 2016
KPTI7.14257.1mPhase 212/31/2016Phase 2 preliminary topline data of Selinexor SOPRA trial for Relapsed/Refractory Acute Myeloid Leukemia (AML) due due 4Q 2016.
KPTI7.14257.1mPhase 1/212/31/2016Phase 1/2 data of Selinexor - STOMP trial for Multiple myeloma due late 2016
KTOV2.9719.6mNDA filing12/31/2016NDA filing of KIT-302 for Osteoarthritis and Hypertension to be submitted by the end of 2016
KURA4.3893.0mPhase 212/31/2016Phase 2 top-line data of Tipifarnib for HRAS mutant solid tumors due 2H 2016
LIFE2.9681.9mPhase 1b/212/31/2016Phase 1b/2 data of Resolaris for Limb girdle muscular dystrophy (LGMD) 2B due 4Q 2016
LJPC16.00308.7mPhase 312/31/2016Phase 3 data of LJPC-501 for Catecholamine-resistant hypotension (CRH) due by end of 2016
LXRX15.411.7bPhase 312/31/2016Phase 3 data of Sotagliflozin for Type 1 Diabetes due 2H 2016
MDGN5.73216.7mPhase 2/312/31/2016Phase 2/3 top-line data of NFC-1 for mGluR mutation positive ADHD are due 2H 2016
MRTX5.09101.3mPhase 212/31/2016Phase 2 initial data of Glesatinib (MGCD265) for NSCLC patients with driver alterations in MET due by end of 2016
MNOV6.68213.9mPhase 2b12/31/2016Phase 2b interim analysis of MN-166 for Progressive multiple sclerosis (progressive MS) due 4Q 2016
NBIX49.084.4bNDA Filing12/31/2016NDA filing of NBI-98854 for Tardive dyskinesia due 2016
NBIX49.084.4bPhase 212/31/2016Phase 2 data of NBI-98854 (Valbenazine) for Tourette syndrome due by end of 2016
NKTR15.392.1bPhase 312/31/2016Bayer Phase 3 program called RESPIRE of Cipro DPI (Cipro Dry Powder Inhaler) for Non-cystic fibrosis bronchiectasis. Data due 2H 2016
NKTR15.392.1bPhase 1/212/31/2016Phase 1/2 initial topline data from the dose escalation stage of NKTR-214 for solid tumors due 2H 2016
NVAX7.442.1bPhase 212/31/2016Phase 2 data of RSV F Vaccine rollover trial for Respiratory Syncytial Virus (RSV) in older adults due 2H 2016
NVLS4.7475.5mPhase 212/31/2016Phase 2 data of N91115 for Cystic Fibrosis due 4Q 2016
OGXI0.9228.4mPhase 212/31/2016Phase 2 data of OGX-427 Borealis-2 trial for advanced or metastatic bladder cancer due 2H 2016
OGXI0.9228.4mPhase 212/31/2016Phase 2 data of Apatorsen plus gemcitabine and carboplatin - Spruce trial for Non-squamous, non-small cell lung cancer (NSCLC) are due 2H 2016
ONCE54.441.7bPhase 1/212/31/2016Phase 1/2 initial data of SPK-CHM for Choroideremia due 2H 2016
ONCE54.441.7bPhase 312/31/2016BLA filing of SPK-RPE65 for Inherited retinal dystrophies due 2H 2016
OPHT63.072.4bPhase 312/31/2016Phase 3 initial topline data of Fovista for Wet-AMD due 4Q 2016
OPK9.895.4bPhase 312/31/2016Phase 3 data of hGH-CTP in adults with growth hormone deficiency likely due 2H 2016
OPXA4.0227.8mPhase 2b12/31/2016Phase 2b top-line data of Tovaxin (Tcelna) for Secondary Progressive MS (SPMS) due 4Q 2016.
OTIC14.67451.2mPhase 212/31/2016Data from Phase 2 trial of OTIPRIO for pediatric patients with acute otitis media with tympanostomy tubes (AOMT) initiated March 2016. Due to be completed 2H 2016
OTIC14.67451.2mPhase 312/31/2016Phase 3 data of OTIPRIO for Acute otitis externa due 4Q 2016
MATN0.7219.4mPhase 1b/212/31/2016Phase 1b/2 data of OXi4503 for Acute myeloid leukemia (AML) due 2016
MATN0.7219.4mPhase 212/31/2016Phase 2 full data of Fosbretabulin for gastrointestinal neuroendocrine tumors due 2H 2016
PBYI34.521.2bPhase 212/31/2016Phase 2 addtional data of neratinib monotherapy with high dose loperamide prophylaxis as an extended adjuvant treatment of early stage HER2-positive breast cancer due 2016
PBYI34.521.2bPhase 212/31/2016Phase 2 data of PB272 SUMMIT trial for HER2 non-amplified breast cancer that has a HER2 mutation due 4Q 2016
PGNX34.52535.5mPhase 312/31/2016Phase 3 interim analysis of 1404 to help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA) due 2H 2016
PLX34.52255.6mPhase 212/31/2016Phase 2 data of PRX-110 for Cystic Fibrosis are due late 2016
PRTK12.83284.6mPhase 312/31/2016Phase 3 data of Sarecycline for Severe acne vulgaris due 2H 2016
PRTO8.01129.6mPhase 312/31/2016Phase 3 data of PRT-201 for Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) due December 2016
PTLA23.931.4bNDA Filing12/31/2016NDA filing of Betrixaban for Venous thromboembolism (VTE) Prevention due 2H 2016
RARE52.322.1bPhase 212/31/2016Phase 2 data of Triheptanoin for Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) due 2H 2016.
RARE52.322.1bPhase 212/31/2016Phase 2 data of UX007 (triheptanoin) for Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS) due 2H 2016
RARE52.322.1bPhase 212/31/2016Phase 2 additional data of KRN23 for Tumor-induced osteomalacia (TIO) due 2H 2016
RDHL11.75151.7mPhase 312/31/2016Phase 3 top-line data of BEKINDA GUARD trial for Gastroenteritis due 2H 2016
RDHL11.75151.7mPhase 312/31/2016Phase 3 interim data fo RHB-104 MAP US trial for Crohn’s disease due 2H 2016
REPH7.9774.8mPhase 312/31/2016Phase 3 top-line data of Intravenous (IV) meloxicam for patients with Acute pain following bunionectomy surgery due by end of 2016 - two Phase 3 trials
RGLS3.42190.0mPhase 212/31/2016Phase 2 interim efficacy and safety data of RG-101 and GSK2878175 for HCV due by end of 2016
RIGL2.23207.3mPhase 212/31/2016Phase 2 data of R348 for Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD) due 2016
RIGL2.23207.3mPhase 212/31/2016Phase 2 data of Fostamatinib for IgA nephropathy due by the end of 2016
RIGL2.23207.3mPhase 212/31/2016Phase 2 data of Fostamatinib for Autoimmune hemolytic anemia (AIHA) from first of two stages due by end of 2016
RNN0.2655.0mPhase 1b/2 12/31/2016Phase 1b/2 interim data of RX-3117 for Relapsed and refractory pancreatic cancer and advanced bladder cancer to be released 2016
RPRX1.7138.0mPhase 212/31/2016Phase 2 data of Proellex for Endometriosis due 2H 2016
RVNC13.57406.9mPhase 212/31/2016Phase 2 final data of RT002 for Moderate to severe glabellar (frown) lines to be released 2H 2016.
RVNC13.57406.9mPhase 212/31/2016Phase 2 further data of RT002 for Cervical dystonia to be released 2H 2016
RXII2.2414.1mPhase 212/31/2016Phase 2 preliminary data of Samcyprone - RXI-SCP-1502 for Cutaneous warts due 2H 2016
RXII2.2414.1mPhase 1/212/31/2016Phase 2 preliminary data of RXI-109-1501 for Retinal scarring due 2H 2016
SAGE43.391.4bPhase 312/31/2016Phase 3 data of SAGE-547 for SRSE due 2H 2016
SGEN44.406.5bPhase 312/31/2016Phase 3 data from ALCANZA trial of ADCETRIS for relapsed CD30-positive cutaneous T-cell lymphoma due 2H 2016
SGYP3.92743.7mPhase 312/31/2016Phase 3 data of Plecanatide for Constipation-predominant irritable bowel syndrome (IBS-C) due 4Q 2016
SNGX0.6520.2mPhase 312/31/2016Phase 3 results of SGX301 (synthetic hypericin) for Cutaneous T-Cell Lymphoma (CTCL) due 2H 2016
TBPH22.261.1bPhase 2a12/31/2016Phase 2a data of TD-6450 for Hepatitis C virus (HCV) due 2016
TCON4.8960.5mPhase 212/31/2016Phase 2 data of TRC105 for Renal Cell Carcinoma due late 2016
TCON4.8960.5mPhase 212/31/2016Phase 2 data of TRC105 and Avastin for Glioblastoma due by the end of 2016
TENX2.6172.3mPhase 312/31/2016Phase 3 top line data of Levosimendan to reduce the incidence of low cardiac output syndrome during cardiac surgery due 4Q 2016
TGTX6.04345.7mPhase 312/31/2016Phase 3 data of TG-1101 and IMBRUVICA (GENUINE trial) for Chronic Lymphocytic Leukemia (CLL) due 2H 2016
VSAR11.22340.5mPhase 312/31/2016Phase 3 interim 6 month height velocity analysis of VRS-317 for Growth hormone deficiency in pediatric patients are due by end of 2016 and top line data on the 12 month height velocity primary endpoint is expected in mid 2017.
VTAE10.66317.9mPhase 212/31/2016Phase 2 topline data of VTP-38543 for Atopic dermatitis due 2H 2016
VTVT5.55186.7mPhase 212/31/2016Phase 2 topline results for TTP273 - LOGRA trial for Type 2 Diabetes are expected at the end of 2016.
VYGR12.66345.4mPhase 1b12/31/2016Phase 1b data of VY-AADC01 for advanced Parkinson's Disease due 4Q 2016
XENE7.33101.9mPhase 212/31/2016Phase 2 data of XEN801 for Acne due 4Q 2016
XLRN33.451.3bPhase 212/31/2016Phase 2 preliminary data of Dalantercept - DART Study for Renal Cell Carcinoma due year end 2016
XOMA0.5669.6mPhase 212/31/2016Phase 2 data of XOMA 358 for Congenital hyperinsulinism are due in 2016
VCEL2.1651.5mPDUFA01/03/2017PDUFA date January 3 2017 of MACI for Focal chondral cartilage defects in the knee.
ANAC99.204.5bPDUFA01/07/2017PDUFA January 7 2017 of Crisaborole Topical Ointment for Mild-to-moderate atopic dermatitis
TSRO92.044.7bPDUFA01/11/2017PDUFA January 11 2017 for Rolapitant - intravenous (IV) for Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients
SGYP3.92743.7mPDUFA01/29/2017PDUFA January 29 2017 for Plecanatide in patients with Chronic idiopathic constipation (CIC)
CYNA16.73195.3mPhase 301/31/2017Phase 3 top-line safety data of APL-130277 - CTH-301 for OFF episodes in patients with Parkinson’s disease due 4Q 2016 or 1Q 2017
BVXV3.4511.7mPhase 2b01/31/2017Phase 2b data of M-001, a universal flu vaccine, are due late 2016 or early 2017
SMMT6.8287.5mPhase 201/31/2017Phase 2 24-week data of Ezutromid for Duchenne muscular dystrophy due January 2017
AKAO3.82110.9mPhase 303/31/2017Phase 3 top-line results of Plazomicin - EPIC trial uin patients with complicated urinary tract infections (cUTI) due 1Q 2017
ARDX10.55372.9mPhase 2b03/31/2016Phase 2b data of Tenapanor for Hyperphosphatemia in end-stage renal disease (ESRD) patients due 1Q 2017
ATRS1.00154.9mNDA filing03/31/2017NDA filing of VIBEX QuickShot for Testosterone deficiency to be filed late 2016 or early 2017
BDSI2.40135.7mPhase 2b03/31/2017Phase 2b data of Clonidine gel for Painful diabetic neuropathy (PDN) due 1Q 2017
CAPR4.2073.8mPhase 203/31/2017Phase 2 six month data of CAP-1002 ALLSTAR trial for Myocardial infarction (heart attack) due 1Q 2017
CAPR4.2073.8mPhase 1/203/31/2017Phase 1/2 data of CAP-1002 HOPE-Duchenne trial for Duchenne Muscular Dystrophy (DMD) due 1Q 2017
CLBS0.5532.1mPhase 203/31/2017Phase 2 initial safety data of CLBS03 for Type 1 diabetes due early 2017
CRBP2.83128.7mPhase 203/31/2017Phase 2 trial of Resunab for Dermatomyositis to be completed 1Q 2017
DERM32.001.1bPhase 303/31/2017Phase 3 data of Cimzia for Moderate-to-severe plaque psoriasis due by end of 1Q 2017
EYEG2.4825.1mPhase 303/31/2017Phase 3 top-line data of EGP-437 for Non-infectious anterior uveitis due 1Q 2017
GWPH93.752.4bPhase 203/31/2017Phase 2 data of GWP42006 for Epilepsy due 1Q 2017
KPTI7.14257.1mPhase 2b03/31/2017Phase 2b preliminary topline data of Selinexor - SADAL trial for Diffuse Large B-Cell Lymphoma (DLBCL) due early 2017
NEOT1.0516.8mPhase 2/403/31/2017Phase 2 data of LIPO-202 for Reduction of central abdominal bulging due in 1Q 2017
NKTR15.392.1bPhase 303/31/2017Phase 3 data of NKTR-181 for lower back pain due early 2017
OCRX2.8161.0mPhase 2b03/31/2017Phase 2b trial of OCR-002 for Hepatic encephalopathy to complete enrolment 4Q 2016. Data due shortly after.
OMED12.26379.5mPhase 203/31/2017Phase 2 data of Tarextumab plus platinum chemotherapy and etoposide for First-line extensive-stage small cell lung cancer due early 2017
PBYI34.521.2bPhase 303/31/2017Phase 3 data of PB272 for Third-line HER2-positive metastatic breast cancer due 4Q 2016 or 1Q 2017
PGNX34.52535.5mPhase 2b03/31/2017Phase 3 top-line data of Azedra for Pheochromocytoma due between December 2016 and March 2017
PTCT7.30270.2mPhase 303/31/2017Phase 3 data of Translarna for Nonsense mutation cystic fibrosis due early 2017
QURE7.37183.0mPhase 1/203/31/2017Phase 1/2 30 month follow up data of AMT-060 for Sanfilippo B due early 2017
RTTR1.3811.4mPhase 2/303/31/2017Phase 2/3 top-line data of RP-G28 for Lactose intolerance are due early 2017
TRVN6.66357.8mPhase 303/31/2017Phase 3 APOLLO-1 and APOLLO-2 top-line data of Oliceridine for Moderate to severe acute pain due 1Q 2017.
VRTX93.2124.0bPhase 303/31/2017Phase 3 data of VX-661 in patients with two Copies of the F508del Mutation are expected by early 2017.
WINT1.9016.1mPhase 2b03/31/2017Phase 2b top-line data of Aerosurf for Respiratory Distress Syndrome due 1Q 2017.
ZSAN1.9018.3mPhase 2 pivotal03/31/2017Pivotal trial of ZP-Triptan for Migraine to be completed 1Q 2017
ABIO2.9926.9mPhase 2b06/30/2017Phase 2b interim analysis of Gencaro - GENETIC-AF trial for Chronic Heart Failure due 2Q 2017
AERI17.91489.8mPhase 306/30/2017Phase 3 Mercury 2 data of Roclatan for Glaucoma due 2Q 2017
AKAO3.82110.9mPhase 306/30/2017Phase 3 data of Plazomicin - CARE trial for serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) due 1H 2017
ALDR27.211.4bPhase 306/30/2017Phase 3 topline data of ALD403 - PROMISE 1 trial for Frequent episodic migraine due 1H 2017
ALNY64.975.7bPhase 306/30/2017Phase 3 data due of Patisiran APOLLO trial for Familial Amyloidotic Polyneuropathy (FAP) in patients with ATTR due mid 2017
ARGS6.63179.3mPhase 306/30/2017Phase 3 overall survival analysis of AGS-003 ADAPT Trial for mRCC due 1H 2017
CEMP17.83886.1mPhase 306/30/2017Phase 3 trial of Taksta for Acute bacterial skin and skin structure infections (ABSSSI) to be completed 1H 2017
CERC2.3921.3mPhase 206/30/2017Phase 2 data of CERC-301 for Major depressive disorder (MDD) due 1H 2017
CERU2.8684.9mPhase 1/206/30/2017Phase 1/2 top-line data of CRLX101, in combination with LYNPARZA for solid tumors due 1H 2017
CLVS14.54575.1mPhase 306/30/2017Pivotal data of Rucaparib ARIEL3 trial for advanced ovarian cancer patients with a BRCA-like mutation due around mid 2017
CYTX2.05399.6mPhase 306/30/2017Phase 3 data of ECCS-50 for Scleroderma due mid 2017
FBIO2.90146.2mPhase 206/30/2017Phase 2 data of Triplex vaccine for CMV control in allogeneic stem cell transplant recipients due 1H 2017
FGEN17.931.2bPhase 206/30/2017Phase 2 data of FG-3019 for Idiopathic pulmonary fibrosis due 1H 2017
FLML12.56530.0mPhase 306/30/2017Phase 3 trial of Micropump Sodium Oxybate for Narcolepsy expected to be completed mid 2017
FOMX7.10220.0mPhase 306/30/2017Phase 3 dosing of FDX101 for Acne initiated May 2016. Data are due 1H 2017
GWPH93.752.4bNDA filing06/30/2017NDA filing of Epidiolex for Dravet Syndrome likely 1H 2017
IDRA1.60197.8mPhase 206/30/2017Phase 2 data of IMO-8400 for Waldenström’s Macroglobulinemia due 1H 2017
IDRA1.60197.8mPhase 206/30/2017Phase 2 data of IMO-8400 for Diffuse Large B-cell Lymphoma (DLBCL) due 1H 2017
IDRA1.60197.8mPhase 1/206/30/2017Phase 1/2 data of IMO-8400 for patients with DLBCL due 1H 2017
IONS27.753.4bPhase 306/30/2017Phase 3 NEURO-TTR trial for familial amyloid polyneuropathy (FAP).to be completed in 1H 2017
IONS27.753.4bPhase 306/30/2017Phase 3 Nusinersen trial data due 1H 2017.CHERISH trial - Children with spinal muscular atrophy (SMA). ENDEAR trial - infants with spinal muscular atrophy SMA Data are due 1H 2017
KPTI7.14257.1mPhase 2/306/30/2017Data from Phase 2 portion of Phase 2/3 trial of Selinexor - SEAL trial in patients with dedifferentiated liposarcoma due mid 2017
MDWD7.75166.9mPhase 306/30/2017Phase 3 topline data of NexoBrid for Severe burns due 1H 2017
OGXI0.9228.4mPhase 306/30/2017Phase 3 data of Custirsen (ENSPIRIT trial) for NSCLC due 1H 2017
OMED12.26379.5mPhase 206/30/2017Phase 2 data of Demcizumab plus Abraxane - YOSEMITE trial for first-line pancreatic cancer are due 1H 2017
PSDV3.49125.4mNDA Filing06/30/2017NDA filing of Medidur for Posterior uveitis planned for 1H or mid 2017
RETA17.56352.9mPhase 206/30/2017Phase 2 initial data of Omaveloxolone - MOXIe trial for Friedreich’s ataxia (FA) due 1H 2017
RETA17.56352.9mPhase 206/30/2017Phase 2 initial data of Omaveloxolone - MOTOR trial for Mitochondrial myopathies (MM) due 1H 2017
TKAI5.47130.2mPhase 306/30/2017Phase 3 topline data of Galeterone for castration-resistant prostate cancer (CRPC) due by mid 2017
VBLT4.1494.7mPhase 306/30/2017Phase 3 interim data of VB-111 for recurrent glioblastoma, or rGBMdue 1H 2017
VSAR11.22340.5mPhase 306/30/2017Phase 3 interim 6 month height velocity analysis of VRS-317 for Growth hormone deficiency in pediatric patients are due by end of 2016 and top line data on the 12 month height velocity primary endpoint is expected in mid 2017.
XENE7.33101.9mPhase 2b06/30/2017Phase 2b data of TV-45070 for Postherpetic neuralgia due 1H 2017
XNCR18.64778.7mPhase 206/30/2017Phase 2 initial data of XmAb5871 for IgG4-Related Disease (IgG4-RD) due 1H 2017
AIMT11.39500.9mPhase 312/31/2017Phase 3 trial of AR101 for Peanut Allergy to be completed 2H 2017
ARDX10.55372.9mPhase 312/31/2017Phase 3 data from two trials of Tenapanor for Constipation-predominant irritable bowel syndrome (IBS-C) due in 2017
AXON13.301.3bPhase 312/31/2017Phase 3 data of RVT-101 - MINDSET trial for patients with Alzheimer's disease are due 2017
AXSM7.94155.7mPhase 312/31/2017Phase 3 trial of AXS-02 for Complex regional pain syndrome (CRPS) expected to be completed by end of 2017
CUR0.2630.2mPhase 212/31/2017Phase 2 data of NSI-189 for Major depressive disorder are due 2H 2017
EARS3.77130.6mPhase 312/31/2017Phase 3 data of AM-111 HEALOS trial for Acute inner ear hearing loss due 2H 2017
ESPR11.31266.4mPhase 312/31/2017Phase 3 long-term safety and tolerability top-line data of Bempedoic acid (ETC-1002-040) in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins due 4Q 2017
EXEL8.592.0bPhase 312/31/2017Phase 3 data of cabozantinib (CELESTIAL trial) for patients with advanced hepatocellular cancer (HCC) due 2017
GNVC0.6114.8mPhase 1/212/31/2017Phase 1/2 trial of CGF166 for hearing loss trial completion due in 2017
GWPH93.752.4bPhase 312/31/2017Phase 3 data of Epidiolex for Tuberous Sclerosis Complex due 2H 2017
IRWD13.842.1bPhase 2b12/31/2017Phase 2b data of IW-3718 for Gastroesophageal reflux disease (GERD) are due in 2017
MACK5.36727.0mPhase 212/31/2017Phase 2 data of MM-302 HERMIONE trial for HER2-positive locally advanced or metastatic breast cancer due 2017
MACK5.36727.0mPhase 212/31/2017Phase 2 data of ONIVYDE for first line pancreatic due 2017
MNTA11.71866.0mPhase 1/212/31/2017Phase 1/2 topline data of Necuparanib (MOM-M402-103) for advanced metastatic pancreatic cancer due 2H 2017
MRUS8.45132.3mPhase 1/212/31/2017Phase 1/2 top-line data of MCLA-128 for HER2-expressing solid tumors due 2H 2017
NBIX49.084.4bNDA Filing12/31/2017NDA filing of Elagolix for Endometriosis due 2017
NBRV8.15174.0mPhase 312/31/2017Phase 3 topline data from two trials of Lefamulin for Moderate to severe Community Acquired Bacterial Pneumonia (CABP) due 2H 2017
NVIV6.57212.6mHDE Submission12/31/2017HDE (Humanitarian Device Exemption) submission of Neuro-Spinal Scaffold in patients with Complete Thoracic AIS A Spinal Cord Injury due in 2017.
OMED12.26379.5mPhase 212/31/2017Phase 2 data of Demcizumab plus carboplatin and pemetrexed - DENALI trial for First-line non-squamous NSCLC are due in late 2017 or in 2018
OTIC14.67451.2mPhase 312/31/2017Phase 3 data from first and second trials of OTO-104 AVERTS-1 and AVERTS-2 for Ménière's disease due 2H 2017
PSTI1.51124.3mPhase 212/31/2017Phase 2 data of PLX-PAD (stem cells) for Intermittent claudication, or IC are due 2017
RARE52.322.1bPhase 312/31/2017Phase 3 data of Aceneuramic acid extended release (Ace-ER) for GNE Myopathy due 2017
RETA17.56352.9mPhase 212/31/2017Phase 2 data of Bardoxolone methyl for Pulmonary hypertension due to interstitial lung disease - PH-ILD due 2H 2017
RETA17.56352.9mPhase 1/212/31/2017Phase 1/2 data of Omaveloxolone - REVEAL trial for Metastatic melanoma due 2H 2017
TBPH22.261.1bPhase 212/31/2017Phase 2 data of Velusetrag (TD-5108) for Gastroparesis due 2017
TBPH22.261.1bPhase 312/31/2017Phase 3 data of Telavancin for Staphylococcus aureus bacteremia due 2017
TBRA10.96120.3mPhase 2a12/31/2017Phase 2a data of Cenicriviroc (CVC) - PERSEUS study for Primary sclerosing cholangitis (PSC) due 2017
TCON4.8960.5mPhase 212/31/2017Phase 2 data of TRC105 and Nexavar for Hepatocellular carcinoma due 2017
VICL4.3941.3mPhase 312/31/2017Phase 3 top line data of ASP0113 Vaccine for Hematopoietic cell transplant recipients due 4Q 2017
AVEO1.0560.4mPhase 303/31/2018Phase 3 data of tivozanib - TIVO-3 trial for third line treatment of patients with renal cell cancer due 1Q 2018
GLMD4.1645.1mPhase 2b03/31/2018Phase 2b Interim analysis of Aramchol for Non-Alcoholic Steatohepatitis (NASH) due December 2016 or early 2017. Final Data due 1Q 2018
PRTA53.352.0bPhase 2b03/31/2018Phase 2b data due late 2017 or early 2018 for NEOD001 for Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
VTVT5.55186.7mPhase 303/31/2018Phase 3 data of Azeliragon - STEADFAST trial for Mild Alzheimer’s disease due late 2017 or early 2018
ALNY64.975.7bPhase 306/30/2018Phase 3 data of Revusiran ENDEAVOUR trial for ATTR in patients with familial amyloidotic cardiomyopathy (FAC) due mid-2018
CNAT2.1947.0mPhase 2b06/30/2018Phase 2b topline data of Emricasan for Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT) due 1H 2018
RETA17.56352.9mPhase 306/30/2018Phase 3 data of Bardoxolone methyl - CATALYST trial for Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH due 1H 2018
SGEN44.406.5bPhase 306/30/2018Phase 3 data of ECHELON-1 trial of ADCETRIS in combination with chemotherapy for Frontline Hodgkin lymphoma due 2017 or by mid 2018
TBPH22.261.1bPhase 306/30/2018Phase 3 data of Telavancin for Bacteremia due 2017 or 2018
VTL6.29193.3mPhase 306/30/2018Phase 3 data of VTI-308 for Alcohol-induced liver decompensation, or AILD due mid 2018
AMRN2.33434.1m12/31/2018REDUCE-IT outcomes trial interim efficacy look by the independent Data Monitoring Committee (DMC) expected around the end of 3Q 2016. If not stopped early, trial due for completion in 2017 and presentation/publication of results in 2018
CNAT2.1947.0mPhase 212/31/2018Phase 2 data of Emricasan for NASH fibrosis - ENCORE-NF trial are due 2018
INCY87.7917.3bPhase 312/31/2018Phase 3 initial data of Epacadostat and Keytruda - ECHO-301for first-line metastatic melanoma due 2018
MACK5.36727.0mPhase 212/31/2018Phase 2 data of MM-121 for Heregulin Positive Non-Small Cell Lung Cancer due 2018
MACK5.36727.0mPhase 212/31/2018Phase 2 data of MM-141 for front line pancreatic cancer due 2018
MGNX28.761.1bPhase 312/31/2018Phase 3 completion of Margetuximab SOPHIA study for metastatic breast cancer expected in 2018
SGEN44.406.5bPhase 312/31/2018Phase 3 data of ADCETRIS in combination with chemotherapy - ECHELON-2 trial in patients with frontline CD30-positive mature T-cell lymphomas are due 2017 or 2018
XNCR18.64778.7mPhase 212/31/2018Phase 2 initial data of XmAb5871 for Systemic Lupus Erythematosus (SLE) due 2018

About the author

Currently residing in New Zealand, Mr. A.Burden holds a Master of Commerce in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.

223 Responses to “FDA Calendar”

  1. Ken says:

    TTNP is slated for Probuphine NDA September 2012, with Pre-NDA meeting with FDA complete. Is there a specific reason this isn’t included on your list?http://www.titanpharm.com/products.htm#gpm1_1

    • admin says:

      Hi Ken,

      Thanks for your message. I only follow companies that are listed on AMEX or NASDAQ. I haven’t followed TTNP as it is OTC listed. However, if an OTC stock has an upcoming major event, such as an NDA filing or PDUFA date, and a reader brings it to my attention then I do make exceptions.

      I’ll add the September event later tonight 🙂

  2. Ken says:

    Thanks. Your site is very helpful keep up the good work!

  3. Firas says:

    Where is the upcoming NDA filling from Spectrum pharmaceutical, belinostat for PTCL.
    It use to be on you list.
    Now i only see a phase 3 result, without any FDA filling to follow, why?

    • admin says:

      Hi Firas,

      Thanks for your enquiry.

      I’m not sure why the entry was deleted but I have re-entered the NDA Filing which is due to filed this year (according to its latest 10-Q) pending positive data from its Phase 3 trial.

  4. AP says:

    Please can you remove old date (Jun Date) and update it.


    • admin says:


      That’s always been a problem with the Calendar. I had a quick look at the entries. Company guidance has a few like APPA re-filing its NDA during mid-2012. I’ve got to put a date in, so for those events I’ve always put June 30 as an estimate as that is “mid-year”, when it could actually be July or even August. Maybe I’ll just change the date to read July 31. What do you (and others) think?

      The other events refer to clinical trial initiations. The problem with these is that some are so minor that some companies don’t release PRs about the initiations until they release their financial reports for that quarter, and we won’t hear from most companies till about early August. So I either wait till then for a company update, or I just delete them off the calendar. Thoughts??

  5. nimer hasan says:

    can you tell me what are the status of anth and dcth on the fda calendar

    • admin says:

      The status of ANTH and DCTH are correct as of their last PRs, although they may provide an update when they provide their 10Qs over the next few weeks.Use the “keyword” function to find ANTH and DCTH. eg. Type “DCTH” in the KEYWORD tool on the FDA Calendar. The KEYWORD function is located immediately above the FDA Calendar menu (Price, ticker, Type, catalyst date, notes)

  6. nimer hasan says:

    thanks for your prompt reply , and would like to know what does it mean for dcth to FILL NDA?AND WONDER IF IT HAS PASSED ANY PHASES ?

    • admin says:

      In late December 2010 DCTH filed their NDA for their chemosaturation system used in the treatment of patients with metastatic melanoma in the liver. Once a company files their NDA, the FDA assigns a PDUFA date to decide whether to approve the product or not. However, in early 2011 the FDA REFUSED to file DCTH’s NDA. This is rare and occurs in less than 5% of cases. They’ll get another chance soon.

  7. nimer hasan says:

    so , i understand if dcth gets the approval to fill their nda ,then they will go to phase one up to phase three later on?

    • admin says:

      The FDA will inform the company whether their NDA filing has been accepted or not, usually 60 days after the filing. If they accept the filing then a PDUFA date (approval date) will be set, which will likely be 10-months following the filing. As an EXAMPLE, if DCTH files NDA 8/31 -> FDA informs company if NDA has been accepted or not by 10/31 -> If NDA filing has been accepted then a PDUFA date of approx 6/30/2013 will be set.

      No further trials will be required PRIOR to the PDUFA date.

      If you have any other questions please feel free to contact me using the “contact” form at the top of the website.

  8. Alpha Global Investments: Options | Alpha Global Investment says:

    […] a strangle, as it is cheaper to execute. Investors who wish to execute this strategy will find that this FDA calendar is a very helpful tool. This calendar, from BioPharmCatalyst, lists all the upcoming catalysts for […]

  9. Chad says:

    “IMGN 12/31/1969” ?

  10. @biochaser says:

    This calendar has saved me a lot of time on research. As they say, time = money. So, I’m making another donation. Keep up the good work.

  11. Chad says:

    VTUS 3/31/12 NDA Filing. I think you mean 3/31/13?

  12. AA says:

    First, thank you for your outstanding calendar.

    Neuralstem (CUR, trades on AMEX) has a few catalysts (see third paragraph from the end of this article):


    Could you please list them?

    Thanks again for this amazing project.

    • admin says:


      Sorry about they dealy.

      Thanks for the feedback. I prefer to list catalysts with links to official PRs/10Qs etc rather than articles. Do you have a PR or filing handy so that I can add it with the catalyst.



  13. Steve says:

    HEB has a FDA advisory panel on December 20th for Ampligen in treating CFS.

    It is listed on page 45 of this transcript from the FDA.


  14. Pharr says:

    Great website! Thanks for your work!

  15. Chad says:

    PPHM – 6/30/12, Shouldn’t this be 13?

  16. Steve says:


    “CorMedix anticipates a final review and determination regarding its CE Mark application by the end of 4Q 2012. ”


  17. sandy says:

    CPRX: Result of Ph II study date is delayed and in Nov 2012

    • admin says:

      Thanks. Am planning a big catch up this weekend. Have started updating my database offline but will update all changes on the website hopefully by the end of this weekend.

  18. Steve says:


    CorMedix anticipates a final review and determination regarding its CE Mark application by the end of 4Q 2012.


  19. rx007 says:

    PDUFA date for desvenlafaxine base ER Tablets of Alembic pharmaceuticals is in december 2012. If you can find out

    • admin says:

      I know little about Alembic. From what I’ve read they filed a aNDA, which is different from a NDA, with no PDUFA date assigned. Have you got any other information, and ideally a link to a press release and then I can investigate further?

      • rx007 says:

        They have also filed, NDA under 505(b)2. Please make some efforts to find PDUFA date

        • admin says:

          I’ve spent quite a bit of time on this but have come up empty. How do you know they have filed an NDA? And how do you know it was filed under 505(b)2? If you could give me the link of your source that would help very much and I could investigate further.

  20. steve says:


    They are now expecting decision on CE Mark in Q1 of 2013, according to their latest 10-Q


    Thanks again for the great calendar.

  21. figurine says:

    thanks for the job! great site 😉

  22. Mike says:

    Thank you for your service. Is there any way you could make your site data exportable to x-cel? This would be fantastic if you could. Thanks again.

    • admin says:


      I had an excel version a few years ago that could be downloaded but found readers were uploading it to their own websites so decided to cease doing that to the general public.


  23. steve says:


    Updated guidance on BL-1020 Phase II/III Schizophrenia interim data to week of March 18, 2013


  24. Jake says:

    To the genius who set up this site and keeps it updated……THANK YOU!

    I have been trading about 95% Bio Tech. stocks for about 5 years now, and this site BY FAR makes me the most money based on the information posted.

    You can check me out at http://www.thelion.com …. Profile name JWT where the trades can not be fudged.

    If you are new here….STAY HERE. This site by far gives you the information you need to make real money….and lots of it.


  25. Joe says:

    This site is so well put together, great work

    • admin says:

      Great to hear the positive feedback. Appreciate it! Currently working on adding more large cap companies to the calendar (e.g GILD/GSK) so it should be more of a complete calendar soon (ish).

  26. steve says:

    CRMD another delay

    As a result, we anticipate final approval for the CE Mark certification for Neutrolin during the second quarter in 2013.


  27. Michael Webb says:

    NVAX – Topline data for RSV in women of childbearing age is 4/30/2013. Topline data for RSV in the elderly is 6/30/2013.

    P.S. I love this calendar. Thank you!

    • admin says:

      Thanks Michael.

      Regarding NVAX, I presume you are asking me to make the 4/30 event clearer for readers, as I already have the event noted. I will add “in women of childbearing age” to the event. As for the 6/30 data release this does not appear in the calendar as it is a Phase 1 data release. To maintain consistency in the calendar I only list upcoming data releases in either Phase 2 or 3 development.



  28. Michael Webb says:

    Got it! Thank you Adam and I did not know that. You’re great dude!

  29. NYS-Esquire says:

    I am new to your site, and love it. The information is formatted in a way that makes it a quick read. However, being new to the site and new to the industry i think it might be helpful to provide new users such as myself with a brief definition of the “type” section. I understand many of your visitors many be more experienced but as a novice, I would love to learn more as a legend or definitions section would prove useful. Thanks. P.S. wonderful work.

  30. John t says:

    Great site, great resource for the bio investor, keep up the good work. Have you added something with respect to Ampligen experts speaking at the FDA workshop (Drug Development for Chronic
    Fatigue Syndrome [CFS] and Myalgic Encephalomyelitis [ME]) next week on April 25-26. This is would be related to Hemispherx new effort to make a precursor to submiiting a formal appeal to their CRL of ampligen. http://www.hemispherx.net/PDF/BioWorld March 14, 2013.pdf

    Thanks so much for your great work!

    • admin says:


      Thank you for the feedback. Regarding HEB, I only list PDUFA dates, Adcom meetings and clinical data release dates in the calendar. I prefer to keep to these guidelines for consistency purposes so unfortunately I will not be able to list the meeting you referred to.


  31. Dr. KP says:

    Great site. One correction… there is no PDUFA for DEPO’s Serada anymore. They changed the name of the drug and got a rejection and have dropped it from their pipeline list.

    • admin says:

      Thanks Dr.KP,

      I know they got a resounding negative vote at the Adcom meeting in March and said that they will no longer be devoting any resources to it, and yes I see that they have removed it from their pipeline. But the PDUFA date still stands, as far as I am aware, even though they will get a CRL. Technically the FDA still need to make a decision even if DEPO have removed it from their pipe. I’m just reading their latest 10-Q and I can’t see any mention of them officially pulling the NDA. Do you know otherwise?



  32. Tia Menon says:

    Why is it the FDA calendar no longer lists the tickers?

  33. Tia Menon says:

    Hi Adam,

    Thank you. Though I am late by 3 years to visit your site, I am happy that I did at least now.

    Great site.

    Thank you.

  34. John t says:

    Hi Sir, again, as always nice to see you are keeping a good work here for an informed audience. I noticed AEZS has another milestone coming up! here it goes: Phase 2 Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia. Estimated Study Completion Date: August 2013. Clinicaltrials ID NCT01614990.

    Thank you Sir.


  35. Adam C says:

    Great Site. I don’t see CRDC upcoming catalysts (Cardica, Inc) of a Premarket Notification 510(k) submission to the FDA in the 3rd quarter of CY13. Here is a reference to that: http://phx.corporate-ir.net/phoenix.zhtml?c=195013&p=irol-newsArticle&ID=1820268&highlight=

    Again, great site.

    Thank you,

    Adam C

    • admin says:

      Thanks Adam,

      Sorry for the delay. I’ve been locked out of my website for the last few days.

      Regarding your enquiry, I only cover PDUFA and catalyst events involving drugs, rather than medical devices due to the difficulty in providing accurate estimates and if I choose to add one (e.g. CRDC) then there will be an expectation to have them all added, which realistically is not possible.

      All the best with your trading!



  36. Juno says:

    Hi Adam,
    Here are a few catalyst for MSTX. I think you always do a good job informing the biotech investor community, and I would like to do my piece to help out.
    1) Sickle Cell Disease – phase 3 NCT01737814 – estimated completion December 2015 ( i think this one is worthy of mention because it is the only company in the world with phase 3 clinical trials for SCD)
    2) Acute Limb Ischemia – initiate POC study in Q1 14
    3) Acute Decompensated Heart Failure – Data from POC study expected in Q1 14.

    This information is based of their recent presentation on September 10 at Rodman and Renshaw Global Investment Conference http://wsw.com/webcast/rrshq23/MSTX/

    Hope this helps!

    • admin says:


      Thank you for your enquiry.

      Please note the FDA Calendar contains dates of data releases and not trial initiations and/or completion of trials. Such events are included in the Company Pipeline Database. For 1) and 2) these events were already entered into the Company Pipeline database http://www.biopharmcatalyst.com/clinical-database/.

      Regarding the catalyst mentioned in 3), I only list data releases for Phase 2 and 3 trials. I do not list pre-clinical catalysts. To maintain consistency, I won’t be including the catalyst as according to the link you sent me the trial is a non-clinical POC trial in dogs.

      Thanks again.


  37. Jonathan Thomas says:

    Awesome Site!

    I had a question about LGND’s PDUFA date for Bazedoxifene. I thought LGND lost all royalty agreements on Bazedoxifene when LGND signed over the rights to manufacture Lasofoxifene to Ethicor on July 24th of this year? And didn’t Pfizer obtain all rights to Bazedoxifene when it acquired Wyeth back in ’09? I think I might have this wrong but if LGND still has some sort of small royalty on Bazedoxifene, is that significant enough for a catalyst play?

    investor.ligand.com – Ligand Signs – License Agreement – Ethicor – Lasofoxifene

    Also, this might be another dumb question, but do you think that the FDA will use their 90-day extension on PFE for Bazedoxifene?

    Thanks for setting up this site, it made me a lot of money on VRX back in May 🙂


  38. Apoca says:

    Hey thanks for a great job. Really appreciate it


  39. Jason says:

    This is a great site, but how often is it updated?

    • admin says:

      Hi Jason,

      The FDA Calendar and Company Pipeline Database are both generally updated daily, or at least Mon-Thur nights. There may be a period during Xmas and other times of the year when I am overseas, which prevents me from updating the site, but it’s generally updated daily. Following reporting season I go through all events in the FDA Calendar to ensure they are up to date as I miss some of the PRs during what is a very busy time of the year. This is what I am currently doing, and the audit should be complete by next week. The news updates on the homepage take time to write up. I try and get a post out Mon-Thur nights but that’s not always possible.




  40. Financial News, Blogs, Twits, Analysis for Momo Trade | Momentum Stocks says:

    […] 6) http://www.biopharmcatalyst.com/fda-calendar/ 7) 8) […]

  41. steve says:

    If pinksheets are allowed ACUS has upcoming catalyst in the first Q of 2014

    The validation process for the MAA has been successfully completed, and the substantive review process is now underway by the Committee for Medicinal Products for Human Use (CHMP). The CHMP opinion is expected in Q1 2014


  42. Pharma stock potential - Page 17 says:

    […] is and FDA calendar you guys might helpful: FDA Calendar | BioPharmCatalyst The stock market is never obvious. It is designed to fool most of the people, most of the […]

  43. Alfredo says:

    Great job. One of the best sources for biotech.


    TRLPF (OTC) has a pdufa date of Feb 28 2014 and is not in the calendar

    Trimel Pharmaceuticals Corporation (OTCMKTS:TRLPF) announced that the New Drug Application (“NDA”) for its bioadhesive intranasal gel testosterone product (“CompleoTRT™”) has been formally accepted for review by the United States Food and Drug Administration (the “FDA”). The NDA is supported by efficacy and safety results from 306 patients who participated in the pivotal Phase III study.

    Additionally, the FDA has confirmed that under the United States Prescription Drug User Fee Act, the NDA will be subject to a standard review and the target action date for the NDA is February 28, 2014.

  44. JERMAINE says:


    • admin says:


      That’s not an easy question to answer.

      In simple terms, when a trial meets an endpoint or shows efficacy with statistical improvement then this is regarded as good news. Likewise, if the trial did not meet its endpoint then this is negative. However, at times, if the good news has been priced in then you may actually see a decline in the price per share. It all depends whether the actual data exceed expectations, or not.

      To fully understand whether the data are good or not, you need to have a good understanding of science and that’s not easy to explain in an email or post.

      If you don’t understand whether the data released are positive or negative, I would highly recommend against investing/trading biotech stocks as you will most likely lose most of your money, especially when the current speculative bubble bursts.

  45. steve says:


    Clinical Trials

    Acasti continues to make significant progress in its research and clinical development program. Recently, Acasti announced that the FDA had given it clearance to initiate a PK trial in the U.S. This is a significant milestone and a key first step towards securing regulatory approval to distribute and market CaPre® as a prescription drug in the U.S. Quintiles, the world’s largest provider of biopharmaceutical development and commercial outsourcing services, has been engaged to conduct the trial. The PK study is expected to start in the second quarter of calendar 2014 and results would be announced in the following quarter.


    Thanks again for the great site

  46. steve says:


    Patient recruitment for the Phase II TRIFECTA study, a randomized, double-blind, placebo-controlled trial is on-going and special focus is being given to recruiting patients in the moderate to severe hypertriglyceridemia population (triglyceride levels over 500 mg/dL). The Corporation continues to aim for trial completion by the first half of calendar 2014


    This was the main trial I wanted to link to for ACST the PK study hasn’t started yet

  47. steve says:

    Sorry about all the duplicate posts. Thanks again

  48. Alex says:

    Hi there,
    I didn’t see ADMP (newly listed to nasdaq from otc). ADAMIS PHARMACEUTICALS has NDA filing for their Epinephrine syringe.
    From report released by CRT capital group few days ago here:

    • In Q1 2014, Adamis plans on filing its epinephrine pre-filled syringe to the FDA via the 505(b)(2) pathway. The Company expects to hear back on an approval decision by late 2014/early 2015. Adamis is partnered with Catalent, who is the contract manufacturer.

    • By mid-2014, Adamis plans to conduct a small, 80-patient study with its Taper Dry owder Inhaler (DPI) for treatment of COPD/asthma. We believe the main purpose of this trial will be to demonstrate the comparable efficacy profile of its recently acquired inhaler vs. GSK’s Advair (the “gold standard” product in the market). We believe this trial could be completed by Q4’14. Adamis will be supplied the product by 3M. ”

    if you can update this that would be great.

    Thank you


    • admin says:

      Thanks ALex,

      I’ve added the NDA filing to the FDA Calendar and APC 1000/3000 to the Company Pipeline database as per information from their SEC filings.

  49. Grant Payne says:

    Hi there,
    I noticed that there is only one upcoming event due end of 2014 for CYTR coming up.
    But I know that, or at least believe, there were other events due in Sept 2014 for a PIII data read out.
    Also, they are supposed to be presenting at ASCO this June, unless they canceled that. But that’d be new to me.

    Can you say whether or not you’ve updated events coming up for CYTR lately, and if so removed some?

    Thanks so much for the great site!!!

    • admin says:

      Hi Grant,

      Currently CYTR do not have any candidates in Phase 3 development. A Phase 3 trial of aldoxorubicin is scheduled to commence this quarter. I keep a record of previous entries and I can say that since late December I haven’t removed any CYTR events. Prior to that, I can’t say for certain as I don’t have those records prior to late Dec 2013. They have a corporate presentation on Monday so they might give an update then.

      As for ASCO, I generally have a seperate ASCO Calendar and will try and place events there. FYI, last year’s is here http://www.biopharmcatalyst.com/asco2013/

      I track about 250 companies so there will always be some catalysts I miss out so am happy to add them if official sources are provided.

      Hope that helps.

  50. John says:

    Wasn’t there an FDA decision for CHTP in mid January? I notice the calendar shows an event on 02/12/14. Just curious, great info here.

    • admin says:

      Hi John,

      The mid-January event was a FDA Advisory Committee meeting where a panel of experts were asked to give their opinion on NORTHERA. The committee returned an overwhelming positive opinion. The FDA now have to make a final decision whether to approve NORTHERA or not. They will take into account the Advisory Committee positive opinion. While they usually make a decision in line with the opinion given by the advisory committee, the FDA do not necessarily need to do so.

      By the way, the FDA decision date (PDUFA) is February 14 (not Feb 12).

  51. Ouwen says:

    It is a good website to give updated information on FDA and phase trials. However, for historical information I can only see FDA approval history while no phase trials’ results, where can I find it? Thanks

  52. Michael says:

    Hi Admin, Love the site and use it frequently!Would you by chance know how long the FDA has to respond/review IGXT response for CRL of migraine film? IGXT submitted it March 3 and I have tried to find this information with no luck. The best I could determine its either 60 days or 6 months, but any help on this would be greatly appreciated!

    • admin says:

      Hi Michael,

      For a resubmission, the FDA should announce a new PDUFA date 2-4 weeks following the resubmission, so you should hear back by the end of the month. The new PDUFA date would be 2-6 months following the resubmission, depending on the type of review.


  53. Paul says:

    Hi Admin.

    I wonder if you have any data, or even a gut feel, for how often the FDA makes a decision BEFORE the PDUFA date that they’ve announced. Is an early decision rare? I’m thinking specifically of MNKD, who had a very positive Advisory Committee meeting on 4/1/14, prior to a scheduled PDUFA date of 4/15. The FDA just moved this back 90 days to 7/15. Speculation is that they weren’t expecting a positive Adcom and are now scrambling, although the official announcement is time to analyze more data. I’m just wondering if under circumstances like this, you’ve seen the FDA not use all their extension time, or whether the tendency is to take it all. Thanks!


    • admin says:

      Hi Paul,

      Apologies about the delay in getting back to you. Yes, I’m sure the FDA weren’t expecting the Adcom result

      Yes, there are times when the FDA do not use all of their extension time, for example UTHR in late 2013, but there are also times when they use all of it. I would say that it is more common for the FDA to use the entire three months (eg VVUS in 2012.).

      I can’t think of a time when the FDA were so negative with their briefing notes but the Adcom issued a positive vote, COUPLED with the fact that the Adcom date was so close to the PDUFA date, so it’s difficult to compare the current situation with those cases listed above.



  54. DrSeattle says:

    Hi, This is wonderful website!
    When do FDA aspect to decide on APPY approval?

  55. SurfingKook says:

    Where is rxii?

  56. G.M. says:

    Hi Admin,
    I have a new catalyst to add to your calendar. These two companies are working in partnership (Intelgenx (IGXT) and RedHill Biopharma (RDHL)) and are expected to produce results of a comparative bioavailability clinical study of their anti-migraine VersaFilm by June 2014. I hope that you can help maintain the good work you are doing, and as always happy to donate to your hard work!!!


  57. taswell thompson says:

    Hey, Im looking for any new info for POZN ?

    • admin says:

      Thank you for your enquiry. Unfortunately, I’m not aware of any new information regarding their manufacturing issues following their recent CRL.



  58. Andrew Downs says:

    Any chance in getting any data on ISR?

    • admin says:


      I just came across ISR yesterday.It looks like that they don’t go through Phase 1-3 testing (from what I’ve just briefly read over the last few minutes) so if this is the case it won’t be covered here. If I’ve read this incorrectly then please let me know and I’ll look into it further.

  59. Andrew Downs says:

    Thanks for the feedback!
    I have one more of interest if you have any data on ONCS

  60. Andrew Downs says:

    IDRA is another of interest for many

  61. Andrew Downs says:

    *DJ BioLine RX Says Upcoming Efficacy Study Expected to Commence in Early 2015 >BLRX

  62. ZIGGY says:

    I try to find info about FDA approval for LPCN1021

    • admin says:


      Lipocine Inc and LPCN1021 have been added to the database. Phase 3 data are due this quarter. Assuming positive data a NDA filing will be submitted in 2H 2015, which would result in a FDA Approval (PDUFA) date in 2H 2016.

  63. ZIGGY says:

    Thank you very much.
    I am watching it very close, see what happen than

  64. ZIGGY says:

    What about nbs? Do you have any data when they will get fda approved?

  65. ZIGGY says:

    would you please explain what is “NDA Filling” and “PDUFA” – I’m kind of new in this bio topic.

    • admin says:

      Apologies about the delay in getting back to you.

      An NDA filing is when a company submits an application for a new drug to be approved. About a couple months after the FDA receives the NDA filing they will set a PDUFA date. The PDUFA is the date when the FDA will issue a decision whether to approve the drug, or not.

  66. Vincent Ippolito says:

    Hi there, I was just inquiring if there is a way I can access the FDA Calendar with the Catalyst Due Date fro previous years rather than only the PDUFA?

    Thank you.

  67. ric says:

    thanks for putting all the hard work you do to keep us updated on new developments in the bio tech industry. I am curious to know how people use this site and interpret whats on your site to make a decision if a stock is a good one to invest or not. Are there other criteria that people look at to make the decision to invest in or not and what would those criteria be if any. Is it multiple news clips, volume, technical analysis of the stock
    what prompts people to jump in or not
    this would be helpful for all beginners

  68. Tony says:

    Admin, remember to add GTHP in the list of upcoming PMA Approvals (January 24, 2015). According to GTHP “We also are anxiously awaiting word from the FDA on our PMA Amendment, which, based on FDA guidelines, could be received by January 24, 2015 or sooner.” (source: http://www.guidedinc.com)

  69. FarmaZutical says:

    Hi, Thanks a lot for your comprehensive list. Good job.

    I want to bring your attention to one of the most promising biotechs I have ever come across. It’s on the OTC and therefore not on your watchlist. But they are looking to uplist in the very near future and I think you would be glad that you invested a few hours on dd at this stage even though they are not on a major excange yet.

    Cellceutix, CTIX, recently published topline results for their breakthrough antibiotic, Brilacidin, and one single dose was found to be equivalent to 7 days of Daptomycin for ABSSSI. Brilacidin is based on a new platform for antibiotics called Defensin Mimetics and the big scoop is that there is close to zero % risk of developing resistance. Hence, this could be the sollution to the superbug problem the World is facing.

    FDA issued a QIDP designation to Brilacidin last week and the company is discussing Phase 3 protocols with FDA probably as I write this to you.

    But Brilacidin is not the only compound in the pipeline. Kevetrin is an anti cancer drug currently in Phase 1 at the Dana Farber Institute under Harvard Uni. Kevetrin activates P53 known as the guardian angel of the genome. The trial is almost fisnished with patients now advancing into cohort 10. Another big catalyst this month.

    So Cellceutic might not fit your Nasdaq requirements but it will soon. And the pipeline is one of the most interesting I have ever seen, so I would certainly find it worthy of a place on your list.

    All best and happy hollidays,

  70. Andrew Downs says:

    Anyone have any thoughts or dates for AEMD?

  71. Chris Hamilton says:

    One I don’t see here is CLDX. Its study completion date is estimated for June 2015 according to clinicaltrials https://clinicaltrials.gov/ct2/show/NCT01498328?term=rindopepimut&rank=1.

    • admin says:


      Thank you for your enquiry. I understand the guidance given by clinicaltrials.gov but in order for the trial to be added to the FDA Calendar the company needs to issue a SEC filing or PR stating that they intend to release data in June. I haven’t seen such a PR but if I have missed it then feel free to send it through.



  72. Andrew Downs says:

    Any info on BIOD?
    They are supposed to provide topline results from phase2a trial of BIOD-531 in Type 2 Diabeties in early January 2015

  73. Andrew Downs says:

    Keep an eye on IPCI
    Lots of new drugs in the pipeline!

  74. Evan says:

    EDAP PMA filing in April. Please add


    • admin says:


      In order for a catalyst to be added to the calendar a company PR with the expected CATALYST DATE is required. If you have such information it would be appreciated if you could send it through and I will add it to the calendar.


  75. Allisondbl says:

    Wonderful site! Keep up the good work!

  76. Rob says:

    SRNE, Tribeca Cynviloq Study Results due in March 2015 as per article.


  77. samuel says:

    Thank you for the updates. Is there anyway I can subscribe to the events in google calendar.

    • admin says:

      Thank you for your enquiry.

      Currently it’s not possible to subscribe to the FDA events in the google calendar. It might be possible in the future to link the PDUFA Calendar to Google but a decision hasn’t been made on that.



  78. RC says:

    JAZZ/CNCE: JZP-386 data expected in Q2 2015. http://finance.yahoo.com/news/jazz-pharmaceuticals-concert-pharmaceuticals-jzp-133000623.html

    You’re welcome! Thank you! You rock! 😀

  79. john says:

    PPHM have a shot?

  80. GB says:

    Noted that the calender states it Generally does not include large cap companies, when/why do you make exceptions to include large cap companies?

    • admin says:


      There’s no single answer to that question but I’ll give it a go. I will update the description in the calendar.

      Yes, originally large cap companies were not included due to the sheer workload required to cover all of them and the fact that there is a limit to the number of companies that can fit into the database. However, coincidentally, just last week a decision was made to include PDUFA dates from as many companies as possible (to the best of my ability), including large cap companies so that is one reason why you will see some included.

      Some large cap companies (e.g. PCYC) were originally small cap when they were entered into the database and still remain so that’s one other reason.

      Also, coincidentally today, I added a few catalysts for AMGN, following their earnings report. I will be aiming to include more but as mentioned there is a limit in terms of the workload required and the number of entries that will fit into the database. If you’re wondering why I chose to add AMGN and not PFE/BMY who also reported yesterday, that’s simply because the catalysts were noted in the AMGN release, saving me time, but there was not a lot of detail regarding upcoming catalysts from the other two.

      Coverage of large cap companies is a work in progress. It’s not possible to include all of them but readers have requested that at least some coverage is given. There is no strict criteria as to which companies will make it into the database or not.



  81. ziggy says:

    Not see in your list BNHLF, they have phase 3 completed.

    • admin says:


      Thank you for your enquiry.

      I see that the stock concerned is listed on OTC. As noted on the FDA Calendar page, “Generally no OTC/PINK companies are listed unless the upcoming catalyst is a PDUFA or Advisory Committee event.” Once they have been assigned a PDUFA date following their BLA filing it’ll appear in the database.


  82. Andrew Downs says:

    $BIOD Received feedback and guidance from FDA on pivotal trial design and toxicology requirements in support of NDA filing for BIOD-531; plans underway to initiate pre-clinical development studies required to initiate pivotal trials and Phase 2b multi-dose study in patients with type 2 diabetes in first half 2015

  83. Andrew Downs says:

    $CPXX catalysts are in their Quarterly and 8k, they have Phase 3 data due in Q2

  84. Vinod says:

    Admin: you are doing a great job. Keep it up. Thanks

  85. Evan says:

    EDAP has a PMA due by April 29th/15 for Ablatherm.

    It’s in the 6K on Nov.6th/14

    Can you add it to the FDA calendar please?


    • admin says:


      I read their PR

      “In order to continue the process, the Company must submit a major amendment, to include the additional information requested by the FDA, by April 29, 2015. This major amendment, which will have the same PMA number as the Company’s initial filing, may extend the FDA review period up to 180 days after submission.”

      This means that they need to submit some information by April 29. No PMA decision will occur on this day.



  86. Jim says:

    Admin, Ocata Therapeutics (OCAT) was up-listed to NASDAQ on 26 Feb 2015. Please add OCAT to your tracking list. Thank you, Jim

  87. julia says:

    AAVL expects topline Ph 2a results in Wet AMD from AVA-101 in mid-2015..

  88. andre says:

    in Q2 of 2015
    will report top-line data for their pivotal Phase 3 clinical study for EBI-005 in pts with moderate to severe dry eye disease

    • andre says:

      from the press release:

      “”We completed patient enrollment in our pivotal Phase 3 clinical study for EBI-005 in patients with moderate to severe dry eye disease and expect to report top-line results from that study in the second quarter of 2015.”

      • admin says:

        Thanks Andre.

        I will wait until FGEN release their 4Q report so I have an up to date link to add to the database. I presume this will be within the next week or so.

        All other changes have been made. Regarding MRNS, I have used information from their PR a couple days ago which included guidance of Phase 3 ganaxolone data due in 1Q 2016.

  89. andre says:

    just reported data in the Phase 2 trial of beloranib, in patients with hypothalamic injury associated obesity (HIAO). You have it in the calendar for 12/31/2015

    Thank you for the great service!

  90. andre says:

    FG-3019: Interim Ph 2 data in neoadjuvant pancreatic cancer (combo w/ gemcitabine and Abraxane)
    FG-3019: Phase 2 data from HBV-associated liver fibrosis


  91. andre says:

    you have Ph 3 for ganaxolone for 6/30/2015.
    However it is indicated for H2 of 2015

    Ph 2 data in PCDH19 female pediatric epilepsy in H1 of 2015

    thanks– andre–

  92. Fezz says:

    Halozyme (HALO) CEO said on 3/2 that she has a meeting “in weeks” and at the end of Q1- with the FDA to discuss a Phase 3 registration study on pegpH20- any word from the FDA?

    Thanks a lot!

  93. Justin says:


    Hi, I’m kind of new at the whole biotech stock trading and I was wondering if you know any stocks with upcoming catalyst that can drive the price up. How you you know what will increase the price and if it will be good news at all? Thanks in advance!


    • admin says:


      An example of an upcoming catalyst is ATHX. They will be reporting data on April 19. If the data are more positive than the market is expecting then you will most likely see an increase in the pps post data release. We do not know for sure if the data will be positive or negative. Prior to the release of data you will see an increase in volume in shares traded and volatility in the pps. Generally, you will see an upward movement in pps prior to the release of data but this does depend on the drug and company.



  94. Top 3 short term Bios PTX, NKTR, and KERX | soyoulikebios says:

    […] with this FDA approved drug.  We have 2 catalysts (from one of my favorite websites: http://www.biopharmcatalyst.com/fda-calendar/) phase 3 data for CIPRO inhale and Amikacin inhale.  Later catalysts include the BAX 855 FDA […]

  95. Martin_435 says:

    HI Admin,

    AEZS said end 2015 is the next FDA analysis…why do you wrote 30.06.15? Do you have other information?


  96. My Top 5 People To Follow On Twitter & Some Free Sites: - John Welsh Trades says:

    […] FDA Calendar – Free Biotech calendar .  Very handy and useful tool.   Donate if you wish. […]

  97. Paul says:


    Just wanted to point out that the link for FATE’s note takes you to XOMA’s quarterly earnings.

  98. Anon says:

    Why is there nothing on Rexahn Pharm (RNN) or Isoray (ISR)?

  99. Tim says:

    Exelexis (exel)
    Fda approval date was moved to later in the year. It was originally supposed to be in August. It would be awesome if you could update this when you get a chance. Thanks

  100. Jeff Bailey says:

    Excellent site. Used info on MNKD clinical trials release date, AdCom, FDA approval, and partnership announcement to time my buy and sell.
    Would like to see you put out a stock calendar that lists the four columns of:
    Clinical trials release date
    AdCom date
    FDA review date
    Any partnership upcoming announcements
    Jeff Bailey

  101. Fortune says:

    keep up the good work,

  102. Eyes on Oct. 23 for Spectrum, Ligand | Awesome Investors says:

    […] in multiple myeloma patients that are unable to receive the more traditional oral therapy. The target date for the decision is October 23, with the company having initially submitted its NDA on the same day […]

  103. Importance of information and time – Ilmari's investment ideas says:

    […] free biotech catalyst calendar you can find from http://www.biopharmcatalyst.com/fda-calendar/  but it is not updated that often so the information is not always accurate and up to date so […]

  104. Tom says:

    Hello Adam,

    In which phase is it best to buy? After I buy, where do I look for good or bad info.

  105. Arty says:

    Hey great work on this website!
    I notice that you give general times such as beginning of year or mid way through year. I’m looking for a specific date that the trial period ends for a certain drug. I’m going through filings for a lot of pharmas, and i’m wondering which filing and where on the filing could i find the deadline for phase 3 trials? Not necessarily when the FDA makes their decision, but the deadline for when the company needs to be done testing for phase 3.

    • admin says:


      Thank you for your enquiry. Regarding your question, 95%+ of companies do not specify the exact date a Phase 3 trial will end. Instead, as you noted, timelines such as “mid xxx” or “2Q” are given. There is no deadline for a company to finish testing for a Phase 3 drug. They can take as long as they wish and it is up to them when they finish it.

      Hope that helps.


  106. Nehalp says:

    Hello – Thanks for having this excellent calendar. Can you please look in ONTX and SYN ? They both were showing before 2016 update.

    • admin says:


      I can’t remember to be honest what was showing before the update but I’ve looked through the most recent PRs and see that there need to be a couple updates. I have made a slight change to ONTX. It’s not major but it appears in both the Company Pipeline Database and FDA Calendar.

      1) ONTX – Oral Rigosertib and azacitidine 09-08 trial – Interim data released December 2015. Full data to be presented 1Q 2016 with Phase 2b to be potentially initiated 2H 2016 subject to financing.

      Regarding SYN, the following two catalysts have been added to both the Company Pipeline Database and FDA Calendar.

      1) Second Phase 2 trial eight week extension data of SYN-010 for Constipation-Predominant Irritable Bowel Syndrome (C-IBS) due 1Q 2016.
      2) Topline results from the second Phase 2a trial of SYN-004 in patients with C. difficile Infection due 1H 2016



  107. Nehalp1 says:

    Thanks Adam,

    Can you please look in BIND ?

  108. Luis says:

    PDUFA moved to May 26

  109. julia says:

    Hello! HRTX is waiting on hernia repair data with HTX-011 in H1 16, not bunionectomy

  110. alex des says:

    $MSTX catalyst are in their quarterly and 8k, they have phase 3 data due in Q2

  111. Tony says:

    Hello Admin,

    SPPI has two PDUFA Dates. One is May 9, 2016, the other is December 11, 2016.


    • admin says:

      Thanks Tony.

      I just looked through their PRs and see that they didn’t release that info, only through an 8-k. I haven’t seen that for a while.

      Appreciate it.


  112. Rusvel T. Pinto Jr says:

    Hello Admin
    Could not find any information about Contravir Pharmaceuticals – CTRV. It has two products in its pipeline FV-100 for the treatment of shingles and CMX-157 for the Hepatitis B virus.

  113. Awaiting Fda Approval Cancer | My Mesotheliom Lawyer says:

    […] FDA Calendar | BioPharmCatalyst – 2016 Biotech Calendar and beyond for your biotech investing. Biotech Catalyst Calendar. Biotech stocks, FDA Approval/PDUFA, Advisory Committee and Phase 2 & 3 trial … […]

  114. Beverly Jedynak says:

    Psdv is NOT scheduled to submit NDA for Medidur in 1H2016. This is expected in first half/mid 2017. The company does plan to submit for approval in Europe later this year.

    • admin says:


      Thank you for pointing out the typographical error. The entry has now been corrected.

      Apologies for the inconvenience caused for you and your investors.

  115. Simon says:


    Please add Arrowhead’s Arrowhead’s ARC 520 Ph. 2 for Hep B finishing around July 2016 at your convenience:


    • admin says:


      Thank you for your notice.

      In order for an event to be listed in the FDA Calendar notification from the company in the form of a PR, SEC filing or presentation is required. It is preferred not to use dates from clinicaltrials.gov as occasionally this does not match information provided by the company.

      If you are aware of a company link (PR, SEC filing) please send it through and it will be added to the FDA Calendar.

  116. Julia says:

    PRQR link leads to Aerie’s PR!

  117. Shawn says:

    Amazing working mate!! Great site

  118. Strat says:

    Anybodies thoughts on outcomes of upcoming decisions for drrx, anth, mrns, lpcn, kpti, gale or adma?

    • admin says:

      GALE – I would presume that the Phase 3 analysis will determine that the trial will continue to completion. i.e not sufficient efficacy to halt the trial, but sufficient enough to proceed through to completion.

      DRRX – Good potential for gains ahead of Adcom. Good potential but I’m never one to hold through catalysts.

      LPCN – Reasons for approval and CRL. Coin toss, leaning towards approval.

      ANTH – Just realised an error made in the database. The trial is Phase 2, not Phase 3.

      I’m no expert though so don’t take my words as gospel! Just an opinion.

  119. Rick says:

    Hi Admin,

    Could you update the dates for July 31, 2016 if new details emerge?

    Thanks so much for providing great information here. Appreciated.

    • admin says:

      Sure, will do Rick.
      I’ll be honest with you though that I don’t expect the companies to provide any further updates until August when they report earnings.
      But in the event updates are provided it will be noted.

  120. Doug says:

    Hi Admin, any news on ELTP due for PDUFA 7/14?

    Great site, thank you.

  121. Richard says:

    Also check out OXIS, one of their drugs is in phase 2, http://bit.ly/29Sg96z

  122. Fkay says:

    Any opinion on TGTX?

    • admin says:


      Thank you for your inquiry.

      The market has obviously a strong negative bias against TGTX at the moment. Although I haven’t looked into the company in any great depth, they do have multiple shots on goal but the fact that there are no near term catalysts and their management hasn’t got the best of reputations has no doubt put downward pressure on their share price. This coupled with the fact that from April 1 to May 5 they sold 212,914 shares of common stock pursuant to their ATM Sales Agreement, which is about 5-10% of their average daily volume, hasn’t helped neither.

      A prediction from here would be nothing but a guess so I’ll leave that for other experts to comment on.


Leave a Reply